News

Ceres Nanosciences receives $500,000 grant to deploy wastewater surveillance products for global health security.

Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, announced today that it has received a $500,000 grant award from the Gates Foundation. This funding will support the deployment of Ceres’ wastewater biosecurity products to global health testing sites across Africa and India.

Global biosecurity has become a top priority, and wastewater surveillance for pathogens in low- and middle-income countries (LMICs) is crucial for pandemic preparedness and prevention. There is a significant need for standardized, low-cost, and easy-to-use wastewater sample processing methods across diverse geographic locations.

This funding will focus on establishing a sustainable supply chain for wastewater testing tools, ensuring that LMICs can continue to monitor priority pathogens beyond the life of the grant. By lowering barriers to adoption, Ceres aims to strengthen national disease surveillance systems and accelerate progress towards global health security.

“Global biosecurity has become a top priority, and wastewater surveillance is one of the most effective ways to monitor pathogens of concern at the population level,” said Ross Dunlap, CEO of Ceres Nanosciences. “By deploying our sample processing products to sites across Africa and India, we can help public agencies act faster, respond to outbreaks earlier, and build resilient surveillance systems that protect millions of lives. We are grateful to the Gates Foundation for supporting this critical need.”

 

Read more here.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like